The Medical Psilocybin Act aims to establish a regulated framework for the use of psilocybin, a naturally occurring psychedelic compound, to treat qualified medical conditions such as major treatment-resistant depression, posttraumatic stress disorder, and substance use disorders. The Act creates a medical psilocybin advisory board to oversee the program, which will include qualified clinicians and producers who are permitted to provide medical services involving psilocybin. The Act also amends the Controlled Substances Act to remove psilocybin and psilocin from the list of controlled substances for the purposes of qualified medical treatment, thereby allowing their legal use in approved settings.

Additionally, the Act provides protections for producers, clinicians, and qualified patients from criminal and civil penalties related to their participation in the program. It establishes two funds: the medical psilocybin treatment equity fund, which will support treatments for qualified patients meeting income requirements, and the medical psilocybin research fund, which will provide grants for research on the medical use of psilocybin. The Act also includes provisions for data collection and annual assessments to evaluate the program's efficacy, ensuring that it meets the needs of qualified patients, particularly those in rural areas or underserved communities.

Statutes affected:
introduced version: 7-9-73.2, 30-31-6
JU substitute: 30-31-6
Final Version: 7-9-73.2, 30-31-6